When There's Not Enough Money To Go Around, NIH Institute's Plan Will Favor Researchers Dependent On Single Grants

WASHINGTON -- Last month 10 scientists got to keep their labs open, thanks to a new policy at the National Institute of General Medical Sciences. The policy lets NIGMS edge further away from scientific merit in funding decisions and ration support so smaller laboratories can survive the increased competition for NIH funds. The beneficiaries are those scientists - like the 10 who didn't make the initial cutoff - who have no other sources of support or who are first-time applicants. The potential

Written byElizabeth Pennisi
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

WASHINGTON -- Last month 10 scientists got to keep their labs open, thanks to a new policy at the National Institute of General Medical Sciences. The policy lets NIGMS edge further away from scientific merit in funding decisions and ration support so smaller laboratories can survive the increased competition for NIH funds. The beneficiaries are those scientists - like the 10 who didn't make the initial cutoff - who have no other sources of support or who are first-time applicants. The potential losers are those with more than $500,000 in grants and those whose grant renewals call for big increases.

The new policy comes in response to increased concern that investigators at small laboratories are being squeezed out of research. Although the NIH budget has grown steadily, it has not kept pace with the increased cost and size of the research enterprise. A decade ago, one in three meritorious grants ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo